CN Bio raises $21 million to scale up organ-on-a-chip technology
Apr 23, 2024 · “We have strategically positioned ourselves accordingly to respond to the market needs and are proud to have received recognition from our major shareholder, CN Innovations, and new institutional investors such as Bayland Capital, to drive this vision forward.
Biopharmaceutical Manufacturing, Upstream, Downstream …
Jan 9, 2025 · News on the biopharmaceutical manufacturing industry, focusing on biologics, technology, upstream/downstream processing, cell culture and regulations
Amgen: Phase 2 results for GLP-1-GIP weight loss drug
Nov 28, 2024 · A number of different drugs, such as Novo Nordisk’s Ozempic, target either the GLP-1 or GIP receptor. Like Eli Lilly’s Mounjaro/Zepbound (tirzepatide), MariTide targets both receptors simultaneously, thereby having a stronger weight loss effect, as suggested by preclinical studies.Next to the dual mechanism of action, the antibody-peptide combination also gives the drug a longer half-life ...
Teva and Sanofi’s IBD drug hits Phase 2 targets
Dec 17, 2024 · “These unprecedented results show that duvakitug could represent the next frontier in treating ulcerative colitis and Crohn’s disease. If the magnitude of effect persists in the phase 3 program, we believe we will have a differentiated medicine for IBD patients who are in urgent need of new options,” said Houman Ashrafian, Executive Vice President, Head of R&D at Sanofi, in a press ...
EMA accepts Marketing Authorization Application for biosimilar to …
Nov 5, 2024 · The European Medicines Agency (EMA) has accepted Alvotech and Advanz Pharma’s marketing authorization application for AVT05, a biosimilar to Johnson & Johnson’s biologic Simponi (golimumab), which is used for the treatment of chronic inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Astellas licenses AviadoBio’s dementia gene therapy candidate
Oct 10, 2024 · “This strategic collaboration will combine our promising gene therapy candidate for FTD-GRN and delivery expertise with Astellas’ global capabilities in development and commercialization of gene therapies.
Biosimilars overview: Formycon assesses the space
Nov 20, 2024 · There are probably 10% to 20% of the competitors in the biosimilars market compared to generics, where there are hundreds of players. I would say in biosimilars there are a good dozen of serious players today, partly because there was some consolidation at …
AbbVie acquires Aliada Therapeutics in $1.4bn deal
Oct 30, 2024 · Based in Boston, US, Aliada Therapeutics was founded in 2021 by Johnson & Johnson together with venture capital firm RA Capital Management. The company’s MODEL platform was originally created at Johnson & Johnson and licensed to Aliada when it was created.
AbbVie’s Produodopa holds potential to become first-choice …
Jan 11, 2024 · AbbVie’s Produodopa is the first-to-market subcutaneous infusion of levodopa. Produodopa uses a VYAFUSER pump that maintains a continuous, steady flow of levodopa throughout the day to control motor fluctuations in the form of …
Ottimo Pharma emerges from stealth mode with promising cancer …
Oct 29, 2024 · UK-based private biotech company Ottimo Pharma has emerged from stealth mode after four years with the appointment of a strong leadership team.